On April 23, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that Shanghai Henlius Biotech, Inc. has presented preclinical data for HLX49, a HER2 biparatopic antibody–drug conjugate (ADC), at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, held in San Diego, USA, from 17-22 April 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
HLX49 is a HER2 biparatopic antibody–drug conjugate (ADC) that incorporates HER2 binding domains from HLX22, a HER2-specific monoclonal antibody. HLX22 is developed in several oncology indications by Henlius under a license from AbClon, Inc., following a discovery collaboration which grants Alligator the right to participate in potential future revenues from both HLX22 and HLX49, and future derivatives. According to Henlius’ official communication, HLX49 is being developed based on Henlius’ proprietary ADC platform. Preclinical HLX49 data was presented in poster format as part of Henlius’ broader early‑stage innovation portfolio at AACR (Free AACR Whitepaper) 2026.
"We view Henlius’ continued expansion of HER2‑directed research, including the presentation of HLX49 at AACR (Free AACR Whitepaper), as a sign of their sustained faith in the underlying biology of HLX22," said Søren Bregenholt, CEO of Alligator Bioscience. "It is encouraging to see Henlius advancing a broad and coherent HER2 strategy while progressing HLX22 in late-stage clinical development."
Under the terms of Alligator’s agreement with AbClon, Alligator is entitled to 35% of AbClon’s revenue from its sublicense to Henlius, including potential milestone payments and royalty revenues. This entitlement applies to HLX22 as well as to products developed by Henlius that are based on, derived from, or incorporate HLX22‑related antibody binding characteristics, which, if such products are successfully developed and approved, could represent a meaningful long‑term revenue opportunity for Alligator.
(Press release, Alligator Bioscience, APR 23, 2026, View Source [SID1234664717])